All In Biotech

Drug Trial Radar · NCT01081145

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised Withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 With Attention Deficit/Hyperactivity Disorder

Last checked: Nov 20, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 528 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

528

Actual

Start

May 11, 2010

Primary completion

Jun 3, 2013

Study completion Jun 3, 2013

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Mar 5, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term maintenance of efficacy of Extended-Release Guanfacine HCl in children and adolescents (6-17 years) with attention-deficit/hyperactivity disorder (ADHD) who respond to an initial open-label, short term treatment with SPD503.

Conditions

  • Attention-deficit/Hyperactivity Disorder

Interventions

  • Extended-release Guanfacine HydrochlorideDrug

    The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.

  • PlaceboOther

    Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Failures During the Double-Blind Randomized-Withdrawal PhaseTime frame: 26 weeks

Locations

81 sites in 10 countries. Site status is shown where the registry gives one.

  • Harmonex Neuroscience Research

    Dothan, Alabama

  • Clinical Study Centers, LLC

    Little Rock, Arkansas

  • Psychiatric Centers at San Diego, Feighner Research

    San Diego, California

  • Encompass Clinical Research - North Coast

    Spring Valley, California

  • Elite Clinical Trials, Inc.

    Wildomar, California

  • Florida Clinical Research Center, LLC

    Bradenton, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Amedica Research Institute, Inc.

    Hialeah, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Florida Clinical Research Center, LLC

    Maitland, Florida

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida

  • AMR-Baber Research Inc.

    Naperville, Illinois

  • Goldpoint Clinical Research, LLC

    Indianapolis, Indiana

  • Louisiana Research Associates, Inc.

    New Orleans, Louisiana

  • Delmarva Family Resources

    Salisbury, Maryland

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Center for Psychiatry and Behavioral Medicine, Inc.

    Las Vegas, Nevada

  • Mount Sinai School of Medicine

    New York, New York

  • Triangle Neuropsychiatry, PLLC

    Durham, North Carolina

  • Ohio State University, Nisonger Center

    Columbus, Ohio

  • IPS Research Company

    Oklahoma City, Oklahoma

  • Oregon Center for Clinical Investigations, Inc. (OCCI, Inc.)

    Salem, Oregon

  • CRI Worldwide, LLC

    Philadelphia, Pennsylvania

  • FutureSearch Clinical Trials

    Austin, Texas

  • ADHD Clinic of San Antonio

    San Antonio, Texas

  • Alliance Research Group, LLC

    Richmond, Virginia

  • Eastside Therapeutic Resource

    Kirkland, Washington

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Huisartspraktijk Jaak Mortelmans

    Ham, Belgium

  • Centre de référence Neuropédiatrique Multidisciplinaire

    Namur, Belgium

  • Psypluriel

    Uccle, Belgium

  • Ziekenhuis Inkendaal Koninklijke Instelling v.z.w.

    Vlezenbeek, Belgium

  • Ziekenhuis Netwerk Antwerpen

    Hoboken, Antwerpen, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Brussels Capital, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Oost-vlaanderen, Belgium

  • Children's and Women's Health Centre of British Columbia

    Vancouver, British Columbia, Canada

  • JPM van Stralen Medicine Professional Corporation

    Ottawa, Ontario, Canada

  • ADHD Clinic/The Kid's Clinic

    Whitby, Ontario, Canada

  • Royal University Hospital

    Saskatoon, Saskatchewan, Canada

  • Centre Hospitalier Universitaire Bocage-Hôpital d'enfants

    Dijon, France

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.